Bank of America’s Roivant Sciences ROIV Stock Holding History

Bank of America’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-240,000	Closed	-$2.8M	–	8192
2023 Q3	$2.8M	Buy	+240,000	New	+$2.71M	﹤0.01%	3945

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America's ROIV Position: Q1 2026 in Review

Bank of America increased its Roivant Sciences (ROIV) stake by 8% in Q1 2026, buying an estimated $6.05M and bringing the position to 3,163,821 shares worth $87.6M. The position accounts for 0.01% of the portfolio, ranked #1205.

Bank of America first reported a position in ROIV in Q1 2022 and has held it in 17 quarters since. 441 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Bank of America held 3,163,821 shares of Roivant Sciences worth $87.6M as of Q1 2026.
Bank of America bought 235,493 Roivant Sciences shares in Q1 2026, an estimated $6.05M.
Roivant Sciences made up 0.01% of Bank of America's portfolio in Q1 2026, its #1205 holding.
Bank of America first reported a position in Roivant Sciences in Q1 2022 and has held it in 17 quarters since.
441 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.